Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders (Q37251153)
Jump to navigation
Jump to search
scientific article published on 08 July 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders |
scientific article published on 08 July 2013 |
Statements
1 reference
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders (English)
1 reference
Kevan C Herold
1 reference
Carla J Greenbaum
1 reference
Stephen E Gitelman
1 reference
Mario R Ehlers
1 reference
Peter A Gottlieb
1 reference
William Hagopian
1 reference
Karen D Boyle
1 reference
Lynette Keyes-Elstein
1 reference
Sudeepta Aggarwal
1 reference
Deborah Phippard
1 reference
Peter H Sayre
1 reference
James McNamara
1 reference
Jeffrey A Bluestone
1 reference
AbATE Study Team
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference